Caroline von Spee-Mayer

Caroline von Spee-Mayer

Auto-generated profile, based on publicly available information

Caroline von Spee-Mayer

Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
CSCaroline von Spee-Mayer
Caroline von Spee-Mayer
ESElise Siegert
Elise Siegert
DADimas Abdirama
Dimas Abdirama
ARAngelika Rose
Angelika Rose
AKAnika Klaus
Anika Klaus
JHJens Y Humrich
Jens Y Humrich
Objectives Defects in regulatory T cell (Treg) biology have been associated with human systemic autoimmune diseases, such as systemic lupus erythematosus (SLE). However, the origin of such Treg defects and their significance in the pathogenesis and treatment of SLE are still poorly understood. Methods Peripheral blood mononuclear cells (PBMC) from 61 patients with SLE and 52 healthy donors and in vitro IL-2 stimulated PBMC were characterised by multicolour flow cytometry. Five patients with refractory SLE were treated daily with subcutaneous injections of 1.5 million IU of human IL-2 (aldesleukin) for five consecutive days, and PBMC were analysed by flow cytometry. Results Patients with SLE develop a progressive homeostatic dysbalance between Treg and conventional CD4+ T cells in correlation with disease activity and in parallel display a substantial reduction of CD25 expression on Treg. These Treg defects resemble hallmarks of IL-2 deficiency and lead to a markedly reduced availability of functionally and metabolically active Treg. In vitro experiments revealed that lack of IL-2 production by CD4+ T cells accounts for the loss of CD25 expression in SLE Treg, which could be selectively reversed by stimulation with low doses of IL-2. Accordingly, treatment of patients with SLE with a low-dose IL-2 regimen selectively corrected Treg defects also in vivo and strongly expanded the Treg population. Conclusions Treg defects in patients with SLE are associated with IL-2 deficiency, and can be corrected with low doses of IL-2. The restoration of endogenous mechanisms of immune tolerance by low-dose IL-2 therapy, thus, proposes a selective biological treatment strategy, which directly addresses the pathophysiology in SLE.

28 December 2009 in Arthritis & Rheumatism
Verified
Journal Article
Closed access
PDF file
OSOmri Snir
Omri Snir
MWMona Widhe
Mona Widhe
MHMonika Hermansson
Monika Hermansson
CSCaroline von Spee
Caroline von Spee
JLJohan Lindberg
Johan Lindberg
VMVivianne Malmström
Vivianne Malmström

1 April 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JHJens Y Humrich
Jens Y Humrich
CSCaroline von Spee-Mayer
Caroline von Spee-Mayer
ESElise Siegert
Elise Siegert
TATobias Alexander
Tobias Alexander
FHFalk Hiepe
Falk Hiepe
GRGabriela Riemekasten
Gabriela Riemekasten

27 February 2013 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
OWOlivia Weigert
Olivia Weigert
CSCaroline von Spee
Caroline von Spee
RUReinmar Undeutsch
Reinmar Undeutsch
LKLutz Kloke
Lutz Kloke
JHJens Y Humrich
Jens Y Humrich
GRGabriela Riemekasten
Gabriela Riemekasten
Introduction: The ability to ameliorate murine lupus renders regulatory T cells (Treg) a promising tool for the treatment of systemic lupus erythematosus (SLE). In consideration to the clinical translation of a Treg-based immunotherapy of SLE, we explored the potential of CD4+Foxp3+ Treg to maintain disease remission after induction of remission with an established cyclophosphamide (CTX) regimen in lupus-prone (NZBxNZW) F1 mice. As a prerequisite for this combined therapy, we also investigated the impact of CTX on the biology of endogenous Treg and conventional CD4+ T cells (Tcon). Methods: Remission of disease was induced in diseased (NZBxNZW) F1 mice with an established CTX regimen consisting of a single dose of glucocorticosteroids followed by five day course with daily injections of CTX. Five days after the last CTX injection, differing amounts of purified CD4+Foxp3+CD25+ Treg were adoptively transferred and clinical parameters, autoantibody titers, the survival and changes in peripheral blood lymphocyte subsets were determined at different time points during the study. The influence of CTX on the numbers, frequencies and proliferation of endogenous Treg and Tcon was analyzed in lymphoid organs by flow cytometry. Results: Apart from abrogating the proliferation of Tcon, we found that treatment with CTX induced also a significant inhibition of Treg proliferation and a decline in Treg numbers in lymphoid organs. Additional adoptive transfer of 1.5 × 106 purified Treg after the CTX regimen significantly increased the survival and prolonged the interval of remission by approximately five weeks compared to mice that received only the CTX regimen. The additional clinical amelioration was associated with an increase in the Treg frequency in the peripheral blood indicating a compensation of CTX-induced Treg deficiency by the Treg transfer. Conclusions: Treg were capable to prolong the interval of remission induced by conventional cytostatic drugs. This study provides valuable information and a first proof-of-concept for the feasibility of a Treg-based immunotherapy in the maintenance of disease remission in SLE.

1 June 2019 in Clinical Immunology
Verified
Journal Article
Closed access
CSCaroline von Spee-Mayer
Caroline von Spee-Mayer
VKVerena Koemm
Verena Koemm
CWClaudia Wehr
Claudia Wehr
SGSigune Goldacker
Sigune Goldacker
GKGerhard Kindle
Gerhard Kindle
KWKlaus Warnatz
Klaus Warnatz

11 October 2019 in Cells
Verified
Journal Article
Open access
PDF file
ARAngelika Rose
Angelika Rose
CSCaroline von Spee-Mayer
Caroline von Spee-Mayer
LKLutz Kloke
Lutz Kloke
KWKaiyin Wu
Kaiyin Wu
AKAnja Kühl
Anja Kühl
JHJens Humrich
Jens Humrich
An acquired deficiency of interleukin-2 (IL-2) and related disturbances in regulatory T cell (Treg) homeostasis play an important role in the pathogenesis of systemic lupus erythematosus (SLE). Low-dose IL-2 therapy was shown to restore Treg homeostasis in patients with active SLE and its clinical efficacy is currently evaluated in clinical trials. Lupus nephritis (LN), a challenging organ manifestation in SLE, is characterized by the infiltration of pathogenic CD4+ T cells into the inflamed kidney. However, the role of the Treg-IL-2 axis in the pathogenesis of LN and the mode of action of IL-2 therapy in the inflamed kidneys are still poorly understood. Using the (NZB × NZW) F1 mouse model of SLE we studied whether intrarenal Treg are affected by a shortage of IL-2 in comparison with lymphatic organs and whether and how intrarenal T cells and renal inflammation can be influenced by IL-2 therapy. We found that intrarenal Treg show phenotypic signs that are reminiscent of IL-2 deprivation in parallel to a progressive hyperactivity of intrarenal conventional CD4+ T cells (Tcon). Short-term IL-2 treatment of mice with active LN induced an expansion the intrarenal Treg population whereas long-term IL-2 treatment reduced the activity and proliferation of intrarenal Tcon, which was accompanied by a clinical and histological amelioration of LN. The association of these immune pathologies with IL-2 deficiency and their reversibility by IL-2 therapy provides important rationales for an IL-2-based immunotherapy of LN.